Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
March 2012, Vol 3, No 2
March 2012, Vol 3, No 2
Adding Bevacizumab to Neoadjuvant Chemotherapy Increases Complete Response Rates
In the Literature
March 2012, Vol 3, No 2
Findings from 2 separate studies have shown that adding the vascular endothelial growth factor inhibitor bevacizumab to adjuvant chemotherapy regimens improves response rates in patients with early-stage breast cancer (Bear HD, et al.
N Engl J Med
. 2012;366:310-320; von Minckwitz G, et al.
N Engl J Med
. 2012;366:299-309).
Read Article
UK Researcher Charges NICE of Misapprehending Value of Costly Cancer Drugs
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
Professor Jonathan Waxman, of Imperial College London, an expert in prostate cancer who founded the Prostate Cancer Charity in England and helped garner support for cancer treatment, has denounced the refusal of the UK National Institute for Health and Clinical Excellence (NICE) to approve the 2 new and expensive prostate cancer drugs approved last year in the United States, saying that NICE "has overregulated and proscribed drugs that offer real advances to people with cancer.
Read Article
Prostate Cancer Foundation Promotes Innovation in Young Investigators
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
The Prostate Cancer Foundation (PCF) is expanding its efforts to encourage innovation in prostate cancer research.
Read Article
Online Genetic Testing Registry New Tool from NIH
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
An online tool launched by the National Institutes of Health (NIH) will help patients, providers, and researchers navigate the rapidly growing landscape of genetic testing, many of them associated with cancer therapy.
Read Article
Despite Lack of Value, Many Providers Recommend Ovarian Cancer Screening
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
Results of a new survey of primary care physicians (PCPs) show that 1 in 3 PCPs believe that ovarian cancer screening is safe and effective, contrary to current evidence. The survey was published in the February 7, 2012, issue of
Annals of Internal Medicine
.
Read Article
Cancer Center Launches Personalized Medicine Institute
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
Moffitt Cancer Center in Tampa, FL, has announced it is launching its Personalized Medicine Institute to advance the fight against cancer, and implementing the promise of personalized cancer care medicine by focusing on innovative biotechnology with its biotechnology subsidiary M2Gen.
Read Article
Novel Biologics Will Reshape Cancer Therapy by 2018, Affordability Key Challenge
Value Propositions
,
Value Peer-spectives
March 2012, Vol 3, No 2
Researchers at Espicom Business Intelligence, a medical and pharmaceutical market analysis company, predict that the development of novel biologic approaches to drug therapy will bring "a sea change" to the approach to cancer therapy, by focusing on controlling solid tumors and the introduction of new drugs that target new pathways.
Read Article
Personalized Vaccine Promising When Added to Sunitinib in Patients with Metastatic Renal-Cell Carcinoma
By
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—A personalized form of immunotherapy added to sunitinib (Sutent) treatment prolonged survival to beyond 30 months in almost half of patients with newly diagnosed, unfavorable-risk metastatic renal-cell carcinoma (mRCC), according to the results of an open-label phase 2 study presented at the 2012 Genitourinary Cancer Symposium.
Read Article
Dose Escalation of Axitinib as Second-Line Treatment of mRCC May Be Needed to Optimize Outcome
By
Wayne Kuznar
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—The dosage of axitinib, the standard second-line treatment for metastatic renal-cell carcinoma (mRCC), should be uptitrated in those patients who fail to achieve therapeutic blood levels on the standard 5-mg daily dosage, according to a new analysis of an international randomized trial presented at the 2012 Genitourinary Cancers Symposium.
Read Article
A Large Subset of Patients with Metastatic Prostate Cancer Go Untreated
Genitourinary Cancers Symposium
March 2012, Vol 3, No 2
San Francisco, CA—More than 1 in 10 patients with metastatic prostate cancer never receive anticancer treatment for their disease, according to an examination of the National Cancer Database.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma